drugset / Trial / NCT01291407

A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer

NCT01291407

Phase 1 Completed 27 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine maximum tolerated dose (MTD), dose limiting toxicities (DLT) and recommend a proper dose for our phase II study of S-1 when combined with radiation therapy for locally advanced or recurrent gastric cancer.

Timeline

Start
2010-11
Primary completion
2013-08
Completion
2013-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject S-1 Small molecule 30 mg/m2 Oral
Subject S-1 Small molecule 40 mg/m2 Oral
Subject S-1 Small molecule 50 mg/m2 Oral
Subject S-1 Small molecule 60 mg/m2 Oral
Subject S-1 Small molecule 70 mg/m2 Oral
Subject S-1 Small molecule 80 mg/m2 Oral

Indications